Pentraxin 3 as a novel marker predicting congestive heart failure in subjects with acute coronary syndrome

Korean Circulation Journal

Volumn 40, Issue 8, 2010, Pages 370-376

  Lee, Dong Hyeon ^a   Jeon, Hui Kyung ^a   You, Ji Han ^a   Park, Mi Yeon ^a   Lee, Seung Jae ^a   Kim, Sung Sik ^a   Shim, Byung Joo ^a   Choi, Yun Seok ^a   Shin, Woo Seung ^a   Lee, Jong Min ^a   Park, Chul Soo ^a   Youn, Ho Joong ^a   Chung, Wook Sung ^a   Kim, Jae Hyung ^a  

^a The Catholic University of Korea College of Medicine   (South Korea)

Author keywords

Acute coronary syndrome; Heart failure; Myocardial infarction; Pentraxin 3

Indexed keywords

ACETYLSALICYLIC ACID; ALBUMIN; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CHOLESTEROL; CLOPIDOGREL; CREATINE KINASE; CREATINE KINASE MB; HEPARIN; PENTRAXIN 3; TRIACYLGLYCEROL; TROPONIN; TROPONIN T;

ACUTE CORONARY SYNDROME; ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; CARDIAC PATIENT; CAUSE OF DEATH; CHOLESTEROL BLOOD LEVEL; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DISEASE REGISTRY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PROGNOSIS; RISK ASSESSMENT; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 77957062497     PISSN: 17385520     EISSN: 17385555     Source Type: Journal    
DOI: 10.4070/kcj.2010.40.8.370     Document Type: Article

References (28)

1. Noh HJ, Kwon NH, Joo SB. Severity of coronary atherosclerosis: influence of metabolic syndrome risk factor clustering and hs-CRP. Korean Circ J 2006;36:802-8.
2. Doo YC, Park WJ, Park SH, et al. The optimal timing to measure C-reactive protein to predict cardiac events in patients with unstable angina. Korean Circ J 2001;31:290-6.
3. Kim TI, Chae SC, Yang DH, et al. Short-term prognostic value of CRP in the patients with acute coronary syndrome. Korean Circ J 2000;30:1387-94.
4. Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB. Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet 1997;349:462-6.
5. Rossi E, Biasucci LM, Citterio F, et al. Risk of myocardial infarction and angina in patients with severe peripheral vascular disease: predictive role of C-reactive protein. Circulation 2002;105:800-3.
6. Rolph MS, Zimmer S, Bottazzi B, Garlanda C, Mantovani A, Hansson GK. Production of the long pentraxin PTX3 in advanced atherosclerotic plaques. Arterioscler Thromb Vasc Biol 2002;22:e10-4.
7. Garlanda C, Bottazzi B, Bastone A, Mantovani A. Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Annu Rev Immunol 2005;23:337-66.
8. Peri G, Introna M, Corradi D, et al. PTX3, a prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans. Circulation 2000;102:636-41.
9. Latini R, Maggioni AP, Peri G, et al. Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction. Circulation 2004;110:2349-54.
10. GRACE Investigators. Rationale and design of the GRACE (global registry of acute coronary events) project: a multinational registry of patients hospitalized with acute coronary syndrome. Am Heart J 2001;141:190-9.
11. Eagle KA, Goodman SG, Avezum A, Budaj A, Sullivan CM, López-Sendón J. Practice variation and missed opportunities for reperfusion in ST-segment-elevation myocardial infarction: findings from the global registry of acute coronary events (GRACE). Lancet 2002;359:373-7.
12. Granger CB, Goldberg RJ, Dabbous O, et al. Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med 2003;163:2345-53.
13. Eagle KA, Lim MJ, Dabbous OH, et al. A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. JAMA 2004;291:2727-33.
14. Das R, Kilcullen N, Morrell C, Robinson MB, Barth JH, Hall AS. The British Cardiac Society Working Group definition of myocardial infarction: implications for practice. Heart 2006;92:21-6.
15. Smith SC Jr, Feldman TE, Hirshfeld JW Jr, et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). J Am Coll Cardiol 2006;47:e1-121.
16. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol 2007;50:e1-157.
17. Antman EM, Hand M, Armstrong PW, et al. 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration With the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction, Writing on Behalf of the 2004 Writing Committee. Circulation 2008;117:296-329.
18. Bassand JP, Hamm CW, Ardissino D, et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J 2007;28:1598-660.
19. King SB 3rd, Smith SC Jr, Hirshfeld JW Jr, et al. 2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on Behalf of the 2005 Writing Committee. Circulation 2008;117:261-95.
20. King SB 3rd, Smith SC Jr, Hirshfeld JW Jr, et al. 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines. J Am Coll Cardiol 2008;51:172-209.
21. de Beer FC, Hind CR, Fox KM, Allan RM, Maseri A, Pepys MB. Measurement of serum C-reactive protein concentration in myocardial ischaemia and infarction. Br Heart J 1982;47:239-43.
22. Verma S, Devaraj S, Jialal I. Is C-reactive protein an innocent bystander or proatherogenic culprit?: C-reactive protein promotes atherothrombosis. Circulation. 2006;113:2135-50.
23. Scirica BM, Morrow DA. Is C-reactive protein an innocent bystander or proatherogenic culprit?: the verdict is still out. Circulation 2006;113:2128-34.
24. Suzuki S, Takeishi Y, Niizeki T, et al. Pentraxin 3, a new marker for vascular inflammation, predicts adverse clinical outcomes in patients with heart failure. Am Heart J 2008;155:75-81. (Pubitemid 350234768)
25. Kotooka N, Inoue T, Aoki S, Anan M, Komoda H, Node K. Prognostic value of pentraxin 3 in patients with chronic heart failure. Int J Cardiol 2008;130:19-22.
26. Inoue K, Sugiyama A, Reid PC, et al. Establishment of a high sensitivity plasma assay for human pentraxin3 as a marker for unstable angina pectoris. Arterioscler Thromb Vasc Biol 2007;27:161-7.
27. Salio M, Chimenti S, De Angelis N, et al. Cardioprotective function of the long pentraxin PTX3 in acute myocardial infarction. Circulation 2008;117:1055-64.
28. Kotooka N, Inoue T, Fujimatsu D, et al. Pentraxin3 is a novel marker for stent-induced inflammation and neointimal thickening. Atherosclerosis 2008;197:368-74.